+91-8668442535
Home / Healthcare / Uterine Le

Uterine Leiomyosarcoma Market By Diagnosis (Sampling & Testing, Imaging Tests, Others) By Treatment (Surgery, Radiotherapy, Chemotherapy, Magnetic Resonance Imaging, Positron Emission Tomography Scan, Others) By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Growth, Share, Opportunities & Competitive Analysis, 2016 – 2028

What treatment options are commonly available in uterine leiomyosarcoma?

Uterine leiomyosarcoma is rare cancer that develops in the uterine lining. This causes severe abdominal bleeding. The bleeding is unusual because it occurs after menopause, is not part of the menstrual cycle, and is accompanied by a vaginal mass.

Treatment of uterine leiomyosarcoma includes laparotomy, which involves making an incision cut to check the inside of the abdomen for signs of disease, as well as pelvic washings, which involve placing saline solutions into the pelvic body cavities and removing them after some time. Additionally, chemotherapy and radiotherapy can be used to stop the growth of cancer cells by using higher-energy X-rays and drugs.

According to the American Cancer Society, chemotherapeutic agents such as Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil), Cisplatin, and Docetaxel (Taxotere) are used to treat uterine leiomyosarcoma.

The market for uterine leiomyosarcoma is expected to rise due to an increase in uterine leiomyosarcoma cases and a growing female population, particularly in highly developed economies. Rising awareness of the importance of female health in high-population countries and rising healthcare expenditures are likely to propel the uterine leiomyosarcoma market forward.

In 2020, an estimated 417,367 people will be diagnosed with uterine cancer worldwide, with an expected 97,370 people dying from the disease. Furthermore, the market is predicted to grow substantially over the forecast period due to the increased focus of the government and healthcare providers.

Massive private-sector investments in the design and development of improved treatments for female genital illnesses, combined with active government recruitment initiatives, may result in uterine leiomyosarcoma market growth.

uterine-leiomyosarcoma-market

What is the Market Size of Uterine Leiomyosarcoma in terms of value?

The global Uterine Leiomyosarcoma Market is projected to increase at a significant CAGR of 5.80 % in the coming years. In 2021, the global Uterine Leiomyosarcoma market was valued at USD XX million and projected to reach USD XX million by 2028.

The demand for Uterine Leiomyosarcoma is projected to increase substantially in the coming years and is presumed to generate revenue opportunities for the key industry players worth USD XX million during the forecast period of 2022 and 2028.

What is the key development for Uterine Leiomyosarcoma?

Given the seriousness of the condition and the importance of women's health, healthcare professionals and governments in various regions, such as North America, Europe, and Asia-Pacific, are launching awareness campaigns.

With the government and healthcare providers putting more emphasis on the industry, it has been indicated that the market will proliferate over the forecast period. For instance, in May 2021, Jemperli (dostarlimab), a programmed death receptor-1 (PD-1)-blocking antibody developed by GlaxoSmithKline (GSK), received approval from both the European Commission (EC) and the Food and Drug Administration (FDA) for the treatment of uterine cancer.

Interesting Facts about the Uterine Leiomyosarcoma Industry

  • The ever-increasing uterine leiomyosarcoma cases, rising female population, increasing awareness of the importance of female health in both developed and developing economies, and increasing healthcare expenditures are all expected to drive market growth for the uterine leiomyosarcoma market.
  • North America region had a significant share in terms of volume and value in the global Uterine Leiomyosarcoma market in 2021 and is projected to continue its dominance over the forecast period.
  • Substantial private sector investments in the design and development of improved therapies for female genital illnesses, together with aggressive government efforts to attract people to the business, may lead to uterine leiomyosarcoma market expansion.
  • The market for uterine leiomyosarcoma is moderately competitive, with many prominent players. Few big players currently dominate the market in terms of market share. There are various products in the trials due to the increased prevalence of cancer; as a result, few other smaller players are projected to enter the market.

Who are the Top 10 players/companies in the Uterine Leiomyosarcoma market regarding value?

The key players in the global Uterine Leiomyosarcoma market in terms of value include Pfizer Inc., Intas Pharmaceuticals Ltd., FMC Corporation, Sun Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., General Electric Company, Koninklijke Philips N.V., Siemens Healthcare Private Limited, Bedford Pharmaceuticals, Merck & Co Inc., and Novartis AG.

These key players are concentrating on new product developments as well as technological innovation to enhance their production in Uterine Leiomyosarcoma to gain a competitive market share at a global level. For instance, in November 2022, Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, United States, reported that the European Commission approved the combination of LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, and KEYTRUDA, an anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, United States, for the treatment of advanced or recurrent uterine cancer in adults with disease progression on or following prior treatment with a platinum‑containing therapy in any setting and who are not candidates for curative surgery or radiation.

Who are the Top 10 Countries in the Uterine Leiomyosarcoma Market?

In the global Uterine Leiomyosarcoma market, the major countries are the US, Germany, France, Italy, Spain, UK, China, India, Japan, and Netherland.

The largest market share is in the United States. It is estimated that 6 out of every 1,000,000 women in the United States experience it each year. Gynecologic oncologists are available in all healthcare organizations to provide the general public with a second opinion and design a treatment plan tailored to the tumor type, cancer stage, and individual needs.

Such initiatives positively impact the uterine cancer treatment and diagnostics market in the U.S. According to the National Cancer Institute, an estimated 60,000 new cases of uterine cancer were diagnosed in the United States in 2019. In some cases, uterine cancer causes gestational trophoblastic disease. Similarly, according to the Department of Health and Human Services, uterine leiomyosarcoma affects an estimated 11.0 % of women between the ages of 15 and 40 in the United States each year.

Which are the Key Treatment Options in the Uterine Leiomyosarcoma Market?

The key treatment options for Uterine Leiomyosarcoma include Surgery, Radiotherapy, Chemotherapy, Magnetic Resonance Imaging, Positron Emission Tomography Scan, and Others. The chemotherapy segment is expected to account for a sizeable portion of the market. This can be attributed to chemotherapy's high adoption rate compared to radiation and surgical treatment.

In addition, the rising prevalence of uterine cancer is driving up the demand for chemotherapy-based drugs. According to the American Cancer Society, there are currently over 600,000 survivors of uterine cancer in the United States. According to the same source, approximately 65,950 new cases of cancer of the body of the uterus (uterine body or corpus) will be diagnosed in the United States in 2022. As a result, the statistics show that the demand for chemotherapy will rise with the growing burden of uterine cancer.

Furthermore, according to a June 2019 published study titled "Adjuvant Chemotherapy plus Radiation for Locally Advanced Uterine Cancer," enrolment concluded with 813 patients; chemotherapy became the mainstay of treatment for high-risk uterine cancer after it became clear that distant metastasis is a key determinant of survival in patients with locally advanced uterine cancer. Such studies show that chemotherapy is effective in the treatment of uterine cancer. As a result of the aforementioned factors, the segment is expected to grow significantly during the forecast period.

What are the Major Driving Factors for the Uterine Leiomyosarcoma Market?

The major drivers of the global Uterine Leiomyosarcoma market, which are projected to drive the market growth, are the rising prevalence of uterine sarcoma and the growing female geriatric population will be the primary drivers of market growth during the forecast period. Rising healthcare expenditures and increased awareness about women's health are expected to drive market growth.

Furthermore, growing awareness of uterine diseases and available therapies, rising healthcare expenditure, innovation in drug development, and subsequent technological advancements are major factors driving the market growth.

What are the Major Restraints for the Uterine Leiomyosarcoma Market?

The key restraints of the global Uterine Leiomyosarcoma market, which is projected to hamper the market growth, are the high cost of treatment, as well as the plethora of side effects associated with uterine sarcoma treatment mechanisms such as nausea and dizziness, combined with misconceptions prevalent in developing regions of the world, may impede global market penetration.

Furthermore, extensive exploitation of patients in the name of chemotherapy and radiotherapy generates negative word of mouth about the entire industry, reducing brand complexity. This is also likely to have a negative impact on market share.

Which Region Dominated the World Uterine Leiomyosarcoma Market?

In 2021, North America expected to dominate the uterine leiomyosarcoma market due to the increased adoption of new technologies and a large patient population.

Furthermore, rising healthcare expenditures and the presence of a developed healthcare sector in the region drive the market growth. According to the National Institutes of Health, the U.S. has a high incidence of uterine cancer due to an increasingly obese population due to unhealthy lifestyles, as well as an increase in the number of post-menopausal women.

The availability of cost-effective diagnosis and treatment options for uterine cancer diagnostic testing is also expected to drive the market growth in the U.S. over the forecast period. The growing geriatric female population is also a significant factor driving the market's growth. In the U.S., an estimated 65,950 people will be diagnosed with uterine leiomyosarcoma. It is the fourth most common cancer in women in this region.

Europe is the second largest market for uterine leiomyosarcoma, owing to increased research and development in the healthcare sector and a large patient population. Furthermore, the growing emphasis on government initiatives to develop therapeutic cancer centers encourages market participants. Drug advancements and uterine cancer innovations drive market growth in developed countries such as Germany, the U.K., and France.

Segmentation of Global Uterine Leiomyosarcoma Market-

Global Uterine Leiomyosarcoma Market – By Diagnosis

  • Sampling & Testing
  • Imaging Tests
  • Others

Global Uterine Leiomyosarcoma Market – By Treatment

  • Surgery
  • Radiotherapy
  • Chemotherapy
  • Magnetic Resonance Imaging
  • Positron Emission Tomography Scan
  • Others

Global Uterine Leiomyosarcoma Market – By Distribution Channels

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Frequently asked questions about the global Uterine Leiomyosarcoma industry

The global uterine leiomyosarcoma market is expected to be impacted significantly by COVID-19.

North America accounted for the highest share in the global Uterine Leiomyosarcoma market in terms of value.

The rising prevalence of uterine leiomyosarcoma and the growing female geriatric population would be the primary drivers of market growth during the forecast period, according to the major drivers of market growth in the global Uterine Leiomyosarcoma market. In addition, growing healthcare costs and more awareness about women's health are likely to propel the market forward.

Chemotherapy segment had a major share in 2021 with more than 38% of the market revenue share.

Sample and testing segment had a major share in 2021 with more than 45% of the market revenue share.

Uterine Leiomyosarcoma Market Scope

Report Attribute Details
Market Value in 2021 USD XX million
Market Value in 2028 USD XX million
CAGR 5.80 %
Benchmarking Year 2021
Past data 2016 – 2021
Forecast period 2022 – 2028
Choose License Type
Trusted By
Godaddy
Published Date:  Jul 2022
Category:  Healthcare
Report ID:   60587
Report Format:   PDF
Pages:   190
Rating:    4.7 (38)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support